Publications by authors named "Emeline Colomba Blameble"
Background: Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking.
Methods: We compared the immune tumor microenvironment of MMRd EC ICI-responders (Rs) and ICI non-responders (NRs), using spatial multiplexed immune profiling and unsupervised hierarchical clustering analysis.
Article Synopsis
- Genomic testing helps treat ovarian cancer, but getting DNA samples from tumors can be hard because of high failure rates.
- This study checked if DNA from fluid in the abdomen (called ascites) can be used to measure genetic changes and find cancer markers.
- Results showed that most samples from patients during chemotherapy had usable tumor DNA, making ascitic fluid a good option for testing instead of doing a biopsy on the tumor itself.
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.
Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.
Background: Despite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU.
View Article and Find Full Text PDF